Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.50 |
| ▸ | ESR1 | P03372 | 10/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208119 | 0.88 | CRBN (0.52) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL30985037 | 0.85 | CRBN (0.54) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL30985245 | 0.85 | CRBN (0.53) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL30984874 | 0.85 | CRBN (0.56) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL27302350 | 0.84 | CRBN (0.55) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL27423866 | 0.84 | CRBN (0.55) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL30985054 | 0.82 | CRBN (0.62) | CRBNESR1IKZF2IKZF1WIZ | |
| SCHEMBL23117841 | 0.81 | CRBN (0.55) | CRBNESR1IKZF2WIZ | |
| SCHEMBL23117840 | 0.81 | CRBN (0.55) | CRBNESR1IKZF2WIZ | |
| SCHEMBL29821966 | 0.81 | CRBN (0.55) | CRBNESR1IKZF2WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383877-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| US-12122763-B2 | Substituted piperidines for androgen receptor degradation | UBIX THERAPEUTICS, INC. (KR) | 2024-10-22 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4186904-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | Ubix Therapeutics, Inc. (KR) | 2023-05-31 | — | — | EP | disclosed |
| CN-116157390-A | Compounds for androgen receptor degradation and pharmaceutical uses thereof | 尤比克斯治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022019597-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | 주식회사 유빅스테라퓨틱스 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | CRBN 1967/4885ESR1 49/4885IKZF2 4559/4885 |
| US-20240383877-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, ESRRA | CRBN 3222/4885ESR1 101/4885IKZF2 3943/4885 |
| US-12122763-B2 | Substituted piperidines for androgen receptor degradation | AR, NR5A1, ESRRA | CRBN 1863/4885ESR1 114/4885IKZF2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.